Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Critical Clinical Evaluation of COVID-19 Patients with Tuberculosis in the Indian Sub-Continent

Author(s): Hemalatha Selvaraj*, Kumudha Damadarosamy, Natarajan Kiruthiga, K.Reeta Vijaya Rani, Kanagaraj Duraisamy, Muralikrishnan Dhanasekaran, Jack Deruiter, Jun Ren, Sivakumar Thangavel and Rachel Parise

Volume 18, Issue 3, 2023

Published on: 15 August, 2022

Page: [276 - 283] Pages: 8

DOI: 10.2174/1574886317666220518092819

Price: $65

Abstract

Background: COVID-19 and tuberculosis (TB) are infectious diseases that predominantly affect the respiratory system with common symptoms, such as cough, fever, and shortness of breath, making them dual burdens.

Methods: This review will discuss the characteristics of the coexistence of TB and new infectious illnesses to provide a framework for addressing the current epidemic. Currently, there are no clear and significant data on COVID-19 infection in TB patients, they may not respond appropriately to drug therapy and may have worse treatment outcomes, especially if their TB treatment is interrupted. Due to emergence, measurements should be taken to minimize TB and COVID-19 transmission in communal settings and health care institutions were created. For both TB and COVID-19, accurate diagnostic testing and well-designed, and established therapeutic strategies are required for effective treatment.

Results: Several health care organizations and networks have specimen transit methods that can be utilized to diagnose and monitor the etiology and progression of COVID 19 and perform contact tracing in developed and underdeveloped nations. Furthermore, patients and health care programs could benefit from increased use of digital health technology, which could improve communication, counseling, treatment, and information management, along with other capabilities to improve health care.

Conclusion: Patients with COVID-19 pulmonary/respiratory problems may seek treatment from respiratory physicians, pulmonologists, TB experts, and even primary health care workers. To have prophylactic and therapeutic strategies against COVID-19, TB patients should take the appropriate health care measures recommended by health care professionals/government officials and maintain their TB therapy as indicated.

Keywords: TB, COVID-19, etiology, pulmonology, WHO, prophylactic.

« Previous Next »
Graphical Abstract

[1]
Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021; 9(6): 622-42.
[http://dx.doi.org/10.1016/S2213-2600(21)00218-6] [PMID: 33965003]
[2]
Peiris S, Mesa H, Aysola A, et al. Pathological findings in organs and tissues of patients with COVID-19: A systematic review. PLoS One 2021; 16(4): e0250708.
[http://dx.doi.org/10.1371/journal.pone.0250708] [PMID: 33909679]
[3]
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565-74.
[http://dx.doi.org/10.1016/S0140-6736(20)30251-8] [PMID: 32007145]
[4]
Group CS. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536-44.
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]
[5]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-80.
[6]
Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun 2020; 525(1): 135-40.
[http://dx.doi.org/10.1016/j.bbrc.2020.02.071] [PMID: 32081428]
[7]
Piplani S, Singh PK, Winkler DA, Petrovsky N. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. Sci Rep 2021; 11(1): 1-13.
[PMID: 33414495]
[8]
Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 2020; 176: 104742.
[http://dx.doi.org/10.1016/j.antiviral.2020.104742] [PMID: 32057769]
[9]
Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res 2021; 128(9): 1323-6.
[http://dx.doi.org/10.1161/CIRCRESAHA.121.318902] [PMID: 33784827]
[10]
Suzuki YJ, Gychka SG. SARS-CoV-2 spike protein elicits cell signaling in human host cells: Implications for possible consequences of COVID-19 vaccines. Vaccines 2021; 9(1): 36.
[http://dx.doi.org/10.3390/vaccines9010036] [PMID: 33440640]
[11]
Ramanathan M, Ferguson ID, Miao W, Khavari PA. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis 2021; 21(8): 1070.
[http://dx.doi.org/10.1016/S1473-3099(21)00262-0] [PMID: 34022142]
[12]
Moderbacher CR, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020; 183(4): 996-1012.
[13]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[14]
Crisan-Dabija R, Grigorescu C, Pavel C-A, et al. Tuberculosis and COVID-19: Lessons from the past viral outbreaks and possible future outcomes. Canadian Respiratory Journal 2020; 2020.
[http://dx.doi.org/10.1155/2020/1401053]
[15]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[16]
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[17]
Regeneron PR. Regeneron’s casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA emergency use authorization 2022.
[18]
Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020; 323(24): 2493-502.
[http://dx.doi.org/10.1001/jama.2020.8630] [PMID: 32392282]
[19]
Cortegiani A, Ippolito M, Greco M, et al. Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Pulmonology 2021; 27(1): 52-66.
[http://dx.doi.org/10.1016/j.pulmoe.2020.07.003] [PMID: 32713784]
[20]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[21]
Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020; 81(2): 318-56.
[http://dx.doi.org/10.1016/j.jinf.2020.04.017] [PMID: 32333918]
[22]
Cantini F, Niccoli L, Nannini C, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect 2020; 81(4): 647-79.
[http://dx.doi.org/10.1016/j.jinf.2020.06.052] [PMID: 32592703]
[23]
Ong CWM, Fox K, Ettorre A, Elkington PT, Friedland JS. Hypoxia increases neutrophil-driven matrix destruction after exposure to Mycobacterium tuberculosis. Sci Rep 2018; 8(1): 11475.
[http://dx.doi.org/10.1038/s41598-018-29659-1] [PMID: 30065292]
[24]
Raman B, Cassar MP, Tunnicliffe EM, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine 2021; 31: 100683.
[http://dx.doi.org/10.1016/j.eclinm.2020.100683] [PMID: 33490928]
[25]
Falasca L, Nardacci R, Colombo D, et al. Postmortem findings in Italian patients with COVID-19: A descriptive full autopsy study of cases with and without comorbidities. J Infect Dis 2020; 222(11): 1807-15.
[http://dx.doi.org/10.1093/infdis/jiaa578] [PMID: 32914853]
[26]
Gerotziafas GT, Catalano M, Colgan MP, et al. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: Position paper from VAS-European independent foundation in angiology/vascular medicine. Thromb Haemost 2020; 120(12): 1597-628.
[http://dx.doi.org/10.1055/s-0040-1715798] [PMID: 32920811]
[27]
Ha H, Kim KH, Park JH, et al. Thromboembolism in Mycobacterium tuberculosis infection: Analysis and literature review. Infect Chemother 2019; 51(2): 142-9.
[http://dx.doi.org/10.3947/ic.2019.51.2.142] [PMID: 31270993]
[28]
Goncalves IM, Alves DC, Carvalho A, do Ceu Brito M, Calvario F, Duarte R. Tuberculosis and venous thromboembolism: A case series. Cases J 2009; 2: 9333.2009.
[http://dx.doi.org/10.1186/1757-1626-2-9333]
[29]
Yasri S, Wiwanitkit V. Tuberculosis and novel Wuhan coronavirus infection: Pathological interrelationship. Indian J Tuberc 2020; 67(2): 264.
[http://dx.doi.org/10.1016/j.ijtb.2020.02.004] [PMID: 32553324]
[30]
Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol 2020; 20(7): 397-8.
[http://dx.doi.org/10.1038/s41577-020-0346-x] [PMID: 32457522]
[31]
Sheerin D, Abhimanyu XW, Johnson WE, Coussens A. Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: A patient-level meta-analysis. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.11.25.20236646]
[32]
Cliff JM, Kaufmann SH, McShane H, van Helden P, O’Garra A. The human immune response to tuberculosis and its treatment: A view from the blood. Immunol Rev 2015; 264(1): 88-102.
[http://dx.doi.org/10.1111/imr.12269] [PMID: 25703554]
[33]
Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020; 26(7): 1017-32.
[http://dx.doi.org/10.1038/s41591-020-0968-3] [PMID: 32651579]
[34]
Masahiro NCS. The travel and tropical medicine manual Fifth Edition. 2017; pp. 356-70.
[35]
Yang H, Lu S. COVID-19 and Tuberculosis. J Transl Int Med 2020; 8(2): 59-65.
[http://dx.doi.org/10.2478/jtim-2020-0010] [PMID: 32983927]
[36]
Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis. Exp Opin Drug Saf 2016; 15(sup1): 11-34.
[http://dx.doi.org/10.1080/14740338.2016.1240783]
[37]
Nanzip BN. Extrapulmonary Tuberculosis (EPTB) Symptoms, Types, Diagnosis, and Treatment, Jotscroll 2020. Available from: https://www.jotscroll.com/forums/11/posts/156/extrapulmonary-tuberculosis-tb-symptoms-types-diagnosis-treatment.html (Accessed on 13 Apr 2022)
[38]
Revised National Tuberculosis Control Programme. Annual status report 2019 Central TB Division, Ministry of Health and Family Welfare, Govt of India, New Delhi, India: RNTCP.
[39]
Hopkins J. University of Medicine. Coronavirus Resource Center.COVID-19 dashboard by the center for Systems Science and Engineering CSSE at Johns Hopkins. 2020. Available from: https://coronavirus.jhu.edu/map.htmlURL(Accessed on 13 Apr 2022).
[40]
WHO. Coronavirus disease 2019 (COVID-19): Situation report. 2020; 73.
[41]
Book W. WHO operational handbook on tuberculosis: Module 1: Prevention: Tuberculosis preventive treatment. 2020.
[42]
Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J 2020; 55(5): 2000547.
[http://dx.doi.org/10.1183/13993003.00547-2020] [PMID: 32217650]
[43]
Wingfield T, Tovar MA, Datta S, Saunders MJ, Evans CA. Addressing social determinants to end tuberculosis. Lancet 2018; 391(10126): 1129-32.
[http://dx.doi.org/10.1016/S0140-6736(18)30484-7] [PMID: 29595481]
[44]
Khurana AK, Aggarwal D. The (in) significance of TB and COVID-19 co-infection. Eur Respir J 2020; 56(2): 2002105.
[http://dx.doi.org/10.1183/13993003.02105-2020] [PMID: 32554537]
[45]
Meo SA, Abukhalaf AA, Alomar AA, AlMutairi FJ, Usmani AM, Klonoff DC. Impact of lockdown on COVID-19 prevalence and mortality during 2020 pandemic: Observational analysis of 27 countries. Eur J Med Res 2020; 25(1): 56.
[http://dx.doi.org/10.1186/s40001-020-00456-9] [PMID: 33168104]
[46]
Indianexpress N.
[47]
Migliori GB, Thong PM, Akkerman O, et al. Worldwide effects of coronavirus disease pandemic on tuberculosis services, January-April 2020. Emerg Infect Dis 2020; 26(11): 2709-12.
[http://dx.doi.org/10.3201/eid2611.203163] [PMID: 32917293]
[48]
Liu D, Shameem M. Future Science 2021.
[49]
India T. Revised national tuberculosis control programme annual status report central TB division, directorate general of health services, ministry of health and family welfare. New Delhi: Central TB Division 2014.
[50]
Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione MC. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J 2020; 56(1): 2001708.
[http://dx.doi.org/10.1183/13993003.01708-2020] [PMID: 32482787]
[51]
Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dis (Lond) 2020; 52(12): 902-7.
[http://dx.doi.org/10.1080/23744235.2020.1806353] [PMID: 32808838]
[52]
Risk Factors for Coronavirus Disease 2019 (COVID-19). Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis 2021; 73(7): e2005-15.
[53]
Casco N, Jorge AL, Palmero D, et al. TB and COVID-19 coinfection: Rationale and aims of a global study. Int J Tuberc Lung Dis 2021; 25(1): 78-80.

Rights & Permissions Print Cite
Article Metrics
25
2
© 2024 Bentham Science Publishers | Privacy Policy